Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Lymphoma 5Neoplasms 2Multiple Myeloma 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × ridaforolimus × Lymphoid × Clear all
NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
46 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
33 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡